BACKGROUND: Alloantibody can lead to antibody-mediated rejection and graft loss in renal transplantation, necessitating an assessment of cross-match compatibility. Within the past decade, more specific solid phase assays of alloantibody have been widely adopted, allowing virtual cross-matching based on unacceptable antigens, the threshold of which is determined by individual centers. METHODS: We examined the clinical outcomes of 482 patients transplanted 2007-2009 in a single center, focusing on 30 patients with weakly reactive donor-specific antibody (DSA) determined prospectively prior to renal transplant. RESULTS: Compared with patients without DSA, patients with weakly reactive DSA do not have increased rates of antibody-mediated rejection, cellular rejection, or graft loss despite conventional immunosuppression utilization. CONCLUSIONS: Using the screening methodology and immunosuppression regimen, we have applied to the patients with weak DSA allows them to be transplanted with equivalent outcomes as those without DSA, despite the overall higher risk characteristics of the patients in the weak DSA group.
BACKGROUND: Alloantibody can lead to antibody-mediated rejection and graft loss in renal transplantation, necessitating an assessment of cross-match compatibility. Within the past decade, more specific solid phase assays of alloantibody have been widely adopted, allowing virtual cross-matching based on unacceptable antigens, the threshold of which is determined by individual centers. METHODS: We examined the clinical outcomes of 482 patients transplanted 2007-2009 in a single center, focusing on 30 patients with weakly reactive donor-specific antibody (DSA) determined prospectively prior to renal transplant. RESULTS: Compared with patients without DSA, patients with weakly reactive DSA do not have increased rates of antibody-mediated rejection, cellular rejection, or graft loss despite conventional immunosuppression utilization. CONCLUSIONS: Using the screening methodology and immunosuppression regimen, we have applied to the patients with weak DSA allows them to be transplanted with equivalent outcomes as those without DSA, despite the overall higher risk characteristics of the patients in the weak DSA group.
Authors: José Luis Caro-Oleas; María Francisca González-Escribano; Francisco Manuel González-Roncero; María José Acevedo-Calado; Virginia Cabello-Chaves; Miguel Ángel Gentil-Govantes; Antonio Núñez-Roldán Journal: Nephrol Dial Transplant Date: 2011-08-02 Impact factor: 5.992
Authors: Eric M Gibney; Linda R Cagle; Brian Freed; Stephanie E Warnell; Larry Chan; Alexander C Wiseman Journal: Nephrol Dial Transplant Date: 2006-04-27 Impact factor: 5.992
Authors: L C Racusen; K Solez; R B Colvin; S M Bonsib; M C Castro; T Cavallo; B P Croker; A J Demetris; C B Drachenberg; A B Fogo; P Furness; L W Gaber; I W Gibson; D Glotz; J C Goldberg; J Grande; P F Halloran; H E Hansen; B Hartley; P J Hayry; C M Hill; E O Hoffman; L G Hunsicker; A S Lindblad; Y Yamaguchi Journal: Kidney Int Date: 1999-02 Impact factor: 10.612
Authors: C Lefaucheur; C Suberbielle-Boissel; G S Hill; D Nochy; J Andrade; C Antoine; C Gautreau; D Charron; D Glotz Journal: Am J Transplant Date: 2007-12-19 Impact factor: 8.086
Authors: Lorraine C Racusen; Robert B Colvin; Kim Solez; Michael J Mihatsch; Philip F Halloran; Patricia M Campbell; Michael J Cecka; Jean-Pierre Cosyns; Anthony J Demetris; Michael C Fishbein; Agnes Fogo; Peter Furness; Ian W Gibson; Denis Glotz; Pekka Hayry; Lawrence Hunsickern; Michael Kashgarian; Ronald Kerman; Alex J Magil; Robert Montgomery; Kunio Morozumi; Volker Nickeleit; Parmjeet Randhawa; Heinz Regele; Daniel Seron; Surya Seshan; Stale Sund; Kiril Trpkov Journal: Am J Transplant Date: 2003-06 Impact factor: 8.086
Authors: Dinesh Kannabhiran; John Lee; Joseph E Schwartz; Rex Friedlander; Meredith Aull; Thangamani Muthukumar; Sean Campbell; David Epstein; Surya V Seshan; Sandip Kapur; Vijay K Sharma; Manikkam Suthanthiran; Darshana Dadhania Journal: Transplantation Date: 2015-06 Impact factor: 4.939
Authors: Sandesh Parajuli; Natalie M Bath; Luis Hidalgo; Glen Leverson; Neetika Garg; Robert R Redfield; Didier A Mandelbrot Journal: Immun Inflamm Dis Date: 2021-08-18